Abstract
The anti-oncogene TP53 is frequently mutated in human cancer, but in hematological malignancies this is arare feature. In acute myeloid leukemia (AML) more than 90% of the patients comprise wild type TP53 in their cancercells, but if TP53 is mutated or deleted the disease is often found to be chemoresistant. In this review we define pro-teomics of the oncogene product p53 as the study of proteins in the p53 regulating signaling networks, as well as the pro-tein study of members of the p53 family itself. Various messenger RNA splice forms as well as a multitude of post-translational modifications give a high number of protein isoforms in the p53 family. Some of the proteomic techniquesallow detection of various isoforms, such as two-dimensional gel electrophoresis in combination with tandem mass spec-trometry (MS/MS) and this methodology may therefore increasingly be used as a diagnostic tool in human disease. Weintroduce the p53 protein as an illustration of the complexity of post-translational m odifications that may affect one highlyconnected protein and discuss the possible impact in AML diagnostics if the p53 profile is reflecting cell stress and statusof signal transduction systems of the malignancy.
Keywords: p53, AML, diagnosis, therapy, signaling networks, two-dimensional electrophoresis
Current Pharmaceutical Biotechnology
Title: Proteomics of p53 in Diagnostics and Therapy of Acute Myeloid Leukemia
Volume: 7 Issue: 3
Author(s): Nina Anensen, Ingvild Haaland, Clive D'Santos, Werner Van Belle and Bjorn Tore Gjertsen
Affiliation:
Keywords: p53, AML, diagnosis, therapy, signaling networks, two-dimensional electrophoresis
Abstract: The anti-oncogene TP53 is frequently mutated in human cancer, but in hematological malignancies this is arare feature. In acute myeloid leukemia (AML) more than 90% of the patients comprise wild type TP53 in their cancercells, but if TP53 is mutated or deleted the disease is often found to be chemoresistant. In this review we define pro-teomics of the oncogene product p53 as the study of proteins in the p53 regulating signaling networks, as well as the pro-tein study of members of the p53 family itself. Various messenger RNA splice forms as well as a multitude of post-translational modifications give a high number of protein isoforms in the p53 family. Some of the proteomic techniquesallow detection of various isoforms, such as two-dimensional gel electrophoresis in combination with tandem mass spec-trometry (MS/MS) and this methodology may therefore increasingly be used as a diagnostic tool in human disease. Weintroduce the p53 protein as an illustration of the complexity of post-translational m odifications that may affect one highlyconnected protein and discuss the possible impact in AML diagnostics if the p53 profile is reflecting cell stress and statusof signal transduction systems of the malignancy.
Export Options
About this article
Cite this article as:
Anensen Nina, Haaland Ingvild, D'Santos Clive, Werner Van Belle and Bjorn Tore Gjertsen , Proteomics of p53 in Diagnostics and Therapy of Acute Myeloid Leukemia, Current Pharmaceutical Biotechnology 2006; 7 (3) . https://dx.doi.org/10.2174/138920106777549731
DOI https://dx.doi.org/10.2174/138920106777549731 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
Call for Papers in Thematic Issues
Artificial Intelligence in Bioinformatics
Bioinformatics is an interdisciplinary field that analyzes and explores biological data. This field combines biology and information system. Artificial Intelligence (AI) has attracted great attention as it tries to replicate human intelligence. It has become common technology for analyzing and solving complex data and problems and encompasses sub-fields of machine ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
JAK2 as a Molecular Marker in Myeloproliferative Diseases
Cardiovascular & Hematological Agents in Medicinal Chemistry Adoptive Immunotherapy for B-cell Malignancies Using CD19- Targeted Chimeric Antigen Receptor T-Cells: A Systematic Review of Efficacy and Safety
Current Medicinal Chemistry Molecular Mechanism of Deguelin in Anti-tumor Effect
Current Pharmaceutical Analysis Controlled-release Particulate Cytokine Adjuvants for Cancer Therapy
Endocrine, Metabolic & Immune Disorders - Drug Targets Saffron-Based Crocin Prevents Early Lesions of Liver Cancer: In vivo, In vitro and Network Analyses
Recent Patents on Anti-Cancer Drug Discovery Pretargeted Radioimmunotherapy with α-Particle Emitting Radionuclides
Current Radiopharmaceuticals Current Options in the Treatment of Mast Cell Mediator-Related Symptoms in Mastocytosis
Inflammation & Allergy - Drug Targets (Discontinued) NBN Polymorphysms and Cancer Susceptibility: A Systematic Review
Current Genomics A Combined Approach with Rituximab Plus Anti-TRAIL-R Agonistic Antibodies for the Treatment of Haematological Malignancies
Current Pharmaceutical Design Cyclophosphamide and/or Anthracyclines Induced Epiphora in Breast Cancer Patients: A Rare Side-effect
Current Drug Safety Molecular Targeted Agents Combined with Chemo-Radiation in the Treatment of Locally Advanced Cervix Cancer
Reviews on Recent Clinical Trials Statins and Type 2 Diabetes Mellitus: An Update After 1 Year
Current Pharmaceutical Design The Extracellular Matrix Regulates Cancer Progression and Therapy Response: Implications for Prognosis and Treatment
Current Pharmaceutical Design Control of Copper Status for Cancer Therapy
Current Cancer Drug Targets Chromatin Remodeling Agents for Cancer Therapy
Reviews on Recent Clinical Trials Mammalian Target of Rapamycin as a Therapeutic Target in Leukemia
Current Molecular Medicine Targeting EGFR in Pancreatic Cancer Treatment
Current Drug Targets Safety of the Thrombopoiesis-Stimulating Agents for the Treatment of Immune Thrombocytopenia
Current Drug Safety A Case of Ischemic Stroke in Acute Promyelocytic Leukemia at Initial Presentation: Relevance of All-Trans Retinoic Acid Treatment
Cardiovascular & Hematological Disorders-Drug Targets Monocyte Dependent Regulation of Autoimmune Inflammation
Current Molecular Medicine